Related Experiment Video
Updated: Mar 12, 2026

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation
Published on: June 5, 2012
Diagnosing schistosomiasis-induced liver morbidity: implications for global control
David U Olveda1, Marianette Inobaya2, Remigio M Olveda3
1Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia.
The enhanced liver fibrosis (ELF) test and specific biomarkers show promise for identifying schistosomiasis-related liver fibrosis. While praziquantel treatment impacts infection, it has limited effect on established morbidity.
Area of Science:
- Parasitology
- Hepatology
- Biomarker Discovery
Background:
- Schistosomiasis causes subclinical liver morbidity.
- The enhanced liver fibrosis (ELF) test was evaluated as a screening tool.
Purpose of the Study:
- To assess the ELF test for screening schistosomiasis-related liver fibrosis.
- To evaluate non-invasive serum biomarkers for hepatic fibrosis.
Main Methods:
- Kato-Katz stool examination for infection prevalence and intensity.
- Ultrasound for assessing hepatic fibrosis.
- Evaluation of serum biomarkers including ELF, TIMP-1, and HA.
Main Results:
- Baseline infection prevalence was 34%, with moderate intensity.
- Hepatic fibrosis occurred in 50% of subjects.
- ELF score, TIMP-1, and HA levels correlated with liver fibrosis grade.
Conclusions:
- Praziquantel treatment had short-term impact on infection, but not established morbidity.
- Higher TIMP-1, HA, and an ELF cut-off of 8 may identify individuals at higher risk for liver disease.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Fungal Phylum Microsporidia
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):

